Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis

References

• LuveroDMilaniALedermannJATreatment options in recurrent ovarian cancer: latest evidence and clinical potentialTher Adv Med Oncol20146522923925342990
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyCancer facts and figures 2008 Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfacts-figures2008/indexAccessed December 31, 2008
   Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 22015 Available from: http://www.nccn.orgAccessed 2, 2015
   Google Scholar
• LedermannJAHackshawAKayeSRandomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancerJ Clin Oncol201129283798380421859991
   PubMed Web of Science ®Google Scholar
• PignataSLorussoDScambiaGPazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomized, open-label, phase 2 trialLancet Oncol201516556156825882986
   PubMed Web of Science ®Google Scholar
• LedermannJAEmbletonACRajaFCediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomized, double-blind, placebo-controlled phase 3 trialLancet2016387100231066107427025186
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trialJ Clin Oncol201432131302130824637997
   PubMed Web of Science ®Google Scholar
• AghajanianCGoffBNycumLRWangYVHusainABlankSVFinal overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancerGynecol Oncol20151391101626271155
   PubMed Web of Science ®Google Scholar
• ColemanRLBradyMFHerzogTJGynecologic oncologyPresented at: Society of Gynecologic Oncology 2015 Annual Meeting on Women’s CancerMarch 28–31, 2015Chicago, IL, USA Abstract 3
   Google Scholar
• KarlanBYAmitMOGaryERRandomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerJ Clin Oncol201230436237122184370
   PubMed Web of Science ®Google Scholar
• MonkBJAndrésPIgnaceVAnti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomized, multicenter, double-blind, placebo-controlled phase 3 trialLancet Oncol201415879980824950985
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab, and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• HolashJMaisonpierrePCComptonDVessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGFScience199928454221994199810373119
   PubMed Web of Science ®Google Scholar
• LokadasanRJamesFVNarayananGPrabhakaranPKTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsEcancer medical science20161062627110282
   PubMedGoogle Scholar
• NilssonMHeymachJVVascular endothelial growth factor (VEGF) pathwayJ Thorac Oncol2006176877017409958
   PubMed Web of Science ®Google Scholar
• SongFEustwoodAJGilbodySDuleyLSuttonAJPublication and related biasesHealth Technol Assess20004101115
   Google Scholar
• ColemanRLMonkBJSoodAKHerzogTJLatest research and treatment of advanced-stage epithelial ovarian cancerNat Rev Clin Oncol201310421122423381004
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• HansenJMColemanRLSoodAKTargeting the tumor microenvironment in ovarian cancerEur J Cancer20165613114326849037
   PubMed Web of Science ®Google Scholar
• McClungECWenhamRMProfile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesInt J Womens Health20168597527051317
   PubMedGoogle Scholar
• HuijbersEJvan BeijnumJRThijssenVLSabrkhanySNowak-SliwinskaPGriffioenAWRole of the tumor stroma in resistance to anti-angiogenic therapyDrug Resist Updat201625263727155374
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• Abu-JawdehGMFaixJDNiloffJStrong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasmsLab Invest1996746110511158667614
   PubMed Web of Science ®Google Scholar
• YamamotoSKonishiIMandaiMExpression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levelsBr J Cancer1997769122112279365173
   PubMed Web of Science ®Google Scholar
• PasquetMGolzioMMeryEHospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesisInt J Cancer201012692090210119739074
   PubMedGoogle Scholar
• FerrissJSJavaJJBookmanMAAscites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers: an NRG oncology/GOG studyGynecol Oncol20151391172226216729
   PubMedGoogle Scholar
• KhaliqueSHookJMLedermannJAMaintenance therapy in ovarian cancerCurr Opin Oncol201426552152825033374
   PubMed Web of Science ®Google Scholar
• QianXQinJPanSLiXPanYMaSMaintenance therapy in ovarian cancer with targeted agents improves PFS and OS: a systematic review and meta-analysisPLoS One2015109e013902626402447
   PubMedGoogle Scholar
• JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience2005307586215637262
   PubMed Web of Science ®Google Scholar
• JainRKNormalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapyNat Med2001798798911533692
   PubMed Web of Science ®Google Scholar
• JubbAMHarrisALBiomarkers to predict the clinical efficacy of bevacizumab in cancerLancet Oncol201011121172118321126687
   PubMed Web of Science ®Google Scholar
• ChanJKKietTKBlansitKMiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancerGynecol Oncol2014133356857424680769
   PubMed Web of Science ®Google Scholar
• CollinsonFHutchinsonMCravenRAPredicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selectionClin Cancer Res201319185227523923935036
   PubMed Web of Science ®Google Scholar